Immix Biopharma, Inc. IMMX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$10.09M+5.3% | -$10.65M-40.4% | -$7.59M-14.5% | -$6.62M-45.8% | -$4.54M+5.6% | ||
| $91.58K+75.7% | $52.11K-46.3% | $96.99K+65.8% | $58.49K+53.3% | $38.15K+85.2% | ||
| $575.57K+0.8% | $570.8K+21.3% | $470.47K-11.6% | $532.25K-38.7% | $868.36K+23.1% | ||
| -$34.15K— | —— | —— | —— | —— | ||
| $432.21K— | —— | $1.04M+97.5% | $524.19K+103% | $258.72K-88.7% | ||
| $866.6K+353% | $191.35K— | —— | —— | $316.62K+158% | ||
| $725+106% | -$12.38K+42.6% | -$21.56K+1.9% | -$21.98K+98.9% | -$2M-991% | ||
| -$35.23K-5.6% | -$33.37K-2.2% | -$32.67K-102% | -$16.14K-2.0% | -$15.83K— | ||
| -$9.83M+10.9% | -$11.03M-86.8% | -$5.91M-11.2% | -$5.31M-215% | -$1.69M-14.2% | ||
| $32.49K-80.3% | $165.13K-55.7% | $372.46K+192% | $127.63K+88.5% | $67.71K-86.6% | ||
| $7.77M+379% | $1.62M0.0% | $1.62M0.0% | $1.62M0.0% | $1.62M— | ||
| $3M— | —— | —— | —— | —— | ||
| -$4.8M+27.8% | -$6.65M-1,684% | -$372.46K-192% | -$127.63K-88.5% | -$67.71K+86.6% | ||
| $33.53K-100.0% | $95.51M+786% | $10.77M— | —— | —— | ||
| $71.09K+108% | $34.25K0.0% | $34.25K0.0% | $34.25K0.0% | $34.25K— | ||
| -$37.56K-100% | $95.67M+802% | $10.61M— | —— | —— | ||
| -$12.81K— | —— | —— | $44.14K+652% | -$8K+68.2% | ||
| -$14.68M-119% | $77.98M+1,710% | $4.31M+201% | -$4.28M-143% | -$1.76M— | ||
| —— | —— | $7.72K-13.4% | $8.91K-9.2% | $9.82K— | ||
| $91.58K+75.7% | $52.11K-46.3% | $96.99K+65.8% | $58.49K+53.3% | $38.15K+85.2% | ||
| $725+106% | -$12.38K+42.6% | -$21.56K+1.9% | -$21.98K+98.9% | -$2M-991% | ||
| -$35.23K-5.6% | -$33.37K-2.2% | -$32.67K-102% | -$16.14K-2.0% | -$15.83K— | ||
| $432.21K— | —— | $1.04M+97.5% | $524.19K+103% | $258.72K-88.7% | ||
| $866.6K+353% | $191.35K— | —— | —— | $316.62K+158% | ||
| $7.77M+379% | $1.62M0.0% | $1.62M0.0% | $1.62M0.0% | $1.62M— | ||
| $3M— | —— | —— | —— | —— | ||
| —— | $31.2K0.0% | $31.2K0.0% | $31.2K0.0% | $31.2K— | ||
| $10.65K— | —— | —— | —— | —— | ||
| $39.19K+1.7% | $38.52K+1.7% | $37.87K+77.4% | $21.34K+1.5% | $21.03K+1.4% | ||
| -$35.23K-5.6% | -$33.37K-2.2% | -$32.67K-102% | -$16.14K-2.0% | -$15.83K— | ||
| $3— | —— | —— | —— | —— | ||
| —— | —— | $7.72K-13.4% | $8.91K-9.2% | $9.82K— | ||
| —— | $49.83K— | —— | $38.45K-89.1% | $354.23K— | ||
| —— | —— | —— | —— | $16— | ||
| -$9.86M+11.9% | -$11.19M-78.3% | -$6.28M-15.5% | -$5.44M-210% | -$1.75M+11.6% | ||
| -$9.86M+11.9% | -$11.19M-78.3% | -$6.28M-15.5% | -$5.44M-210% | -$1.75M+11.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Immix Biopharma, Inc. generate?
- Immix Biopharma, Inc. (IMMX) generated -$32.1M in operating cash flow over the trailing twelve months.
- What is Immix Biopharma, Inc.'s free cash flow?
- After $697.7K of capital expenditures, Immix Biopharma, Inc.'s free cash flow was -$32.8M over the trailing twelve months, down 144.6% year over year.
- Where does Immix Biopharma, Inc.'s cash flow data come from?
- Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.